[go: up one dir, main page]

MX352871B - Método para disminuir inmunogenicidad. - Google Patents

Método para disminuir inmunogenicidad.

Info

Publication number
MX352871B
MX352871B MX2015010691A MX2015010691A MX352871B MX 352871 B MX352871 B MX 352871B MX 2015010691 A MX2015010691 A MX 2015010691A MX 2015010691 A MX2015010691 A MX 2015010691A MX 352871 B MX352871 B MX 352871B
Authority
MX
Mexico
Prior art keywords
decreasing immunogenicity
immunogenicity
decreasing
disclosed
variable domains
Prior art date
Application number
MX2015010691A
Other languages
English (en)
Inventor
Borras Leonardo
Urech David
Gunde Tea
Original Assignee
Esbatech Alcon Biomed Res Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Alcon Biomed Res Unit filed Critical Esbatech Alcon Biomed Res Unit
Publication of MX352871B publication Critical patent/MX352871B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un anticuerpo de cadena única (scFv), en donde la scFv comprende una cadena ligera variable que comprende una serina en la posición 101 (numeración AHo) y una cadena pesada variable que comprende Serina (S) en la posición de la cadena pesada de aminoácido 12, Treonina (T) en la posición de la cadena pesada de aminoácido 103, y Treonina (T) en la posición de la cadena pesada de aminoácido 144 (numeración AHo).
MX2015010691A 2009-12-23 2010-12-21 Método para disminuir inmunogenicidad. MX352871B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28944609P 2009-12-23 2009-12-23
PCT/CH2010/000326 WO2011075861A1 (en) 2009-12-23 2010-12-21 Method for decreasing immunogenicity

Publications (1)

Publication Number Publication Date
MX352871B true MX352871B (es) 2017-12-13

Family

ID=43733894

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015010691A MX352871B (es) 2009-12-23 2010-12-21 Método para disminuir inmunogenicidad.
MX2012005345A MX2012005345A (es) 2009-12-23 2010-12-21 Metodo para disminuir inmunogenicidad.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012005345A MX2012005345A (es) 2009-12-23 2010-12-21 Metodo para disminuir inmunogenicidad.

Country Status (17)

Country Link
US (4) US8796425B2 (es)
EP (3) EP4219545A1 (es)
JP (6) JP5914353B2 (es)
KR (3) KR101758703B1 (es)
CN (2) CN109293768A (es)
AR (1) AR079700A1 (es)
AU (1) AU2010335950B2 (es)
BR (1) BR112012017051A2 (es)
CA (1) CA2777527C (es)
CL (1) CL2012001696A1 (es)
MX (2) MX352871B (es)
PH (1) PH12012500794A1 (es)
RU (1) RU2585534C2 (es)
TW (3) TWI662128B (es)
UY (2) UY39290A (es)
WO (1) WO2011075861A1 (es)
ZA (4) ZA201202299B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2752428T1 (sl) * 2008-06-25 2020-03-31 Novartis Ag Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
LT3216803T (lt) * 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
AU2009264564B2 (en) * 2008-06-25 2014-05-08 Novartis Ag Stable and soluble antibodies inhibiting TNFalpha
JP5914353B2 (ja) * 2009-12-23 2016-05-11 エスバテック − ア ノバルティス カンパニー エルエルシー 免疫原性を減少させるための方法
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
SG194982A1 (en) * 2011-06-23 2013-12-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
RS63085B1 (sr) 2014-05-16 2022-04-29 Ablynx Nv Varijabilni domeni imunoglobulina
EP3143403B1 (en) 2014-05-16 2021-10-27 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
BR112018008754A2 (pt) 2015-10-30 2018-10-30 Ablynx Nv polipeptídeo contra il-23
SG10201911035QA (en) 2015-11-18 2020-01-30 Merck Sharp & Dohme Pd1 and/or lag3 binders
CN108289943B (zh) 2015-12-04 2023-06-20 勃林格殷格翰国际有限公司 在肿瘤细胞中拮抗wnt信号传递的双互补位多肽
BR112019000166A2 (pt) 2016-07-06 2019-10-01 Celgene Corp anticorpos com baixa imunogenicidade e usos dos mesmos
ES2979194T3 (es) 2017-05-31 2024-09-24 Boehringer Ingelheim Int Polipéptidos que antagonizan la señalización WNT en células tumorales
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
KR102567962B1 (ko) * 2018-07-18 2023-08-16 주식회사 엘지에너지솔루션 리튬 이차전지용 바나듐 양극의 전기화학적 전처리 방법 및 이에 의해 전처리된 리튬 이차전지용 바나듐 양극
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
GB201918279D0 (en) * 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
WO2022136693A1 (en) 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
KR20230125239A (ko) * 2020-12-23 2023-08-29 누맙 세러퓨틱스 아게 면역원성이 감소된 항체 가변 도메인 및 항체
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
US20250051826A1 (en) 2021-12-13 2025-02-13 Heraeus Medical Gmbh Tests and methods for detecting bacterial infection
IL316376A (en) 2022-05-06 2024-12-01 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4273162A1 (en) 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI944314A7 (fi) 1992-03-18 1994-09-16 Biomira Inc Vasta-aineen immunogeenisyyden selektiivinen muuttaminen
ATE253593T1 (de) * 1996-07-16 2003-11-15 Plueckthun Andreas Prof Dr Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
BR0207283A (pt) * 2001-02-19 2004-08-17 Merck Patent Gmbh Anticorpos anti-egfr modificados com imunogenicidade reduzida
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
MXPA06001634A (es) * 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
NZ581470A (en) * 2007-06-25 2013-04-26 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
US8243678B2 (en) * 2008-03-10 2012-08-14 Motorola Mobility, Inc. Hierarchical pilot structure in wireless communication systems
AU2009264564B2 (en) * 2008-06-25 2014-05-08 Novartis Ag Stable and soluble antibodies inhibiting TNFalpha
RU2514658C2 (ru) 2008-06-25 2014-04-27 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Оптимизация растворимости иммуносвязывающих средств
SI2752428T1 (sl) * 2008-06-25 2020-03-31 Novartis Ag Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
JP5914353B2 (ja) * 2009-12-23 2016-05-11 エスバテック − ア ノバルティス カンパニー エルエルシー 免疫原性を減少させるための方法

Also Published As

Publication number Publication date
JP2019141071A (ja) 2019-08-29
AR079700A1 (es) 2012-02-15
JP2016094487A (ja) 2016-05-26
TWI633184B (zh) 2018-08-21
JP2015131855A (ja) 2015-07-23
TWI662128B (zh) 2019-06-11
US9803027B2 (en) 2017-10-31
UY39290A (es) 2021-07-30
CA2777527A1 (en) 2011-06-30
CN102686608A (zh) 2012-09-19
JP6815083B2 (ja) 2021-01-20
US20110152505A1 (en) 2011-06-23
AU2010335950A1 (en) 2012-07-19
PH12012500794A1 (en) 2012-11-26
KR101721187B1 (ko) 2017-03-29
TW201125975A (en) 2011-08-01
ZA202006532B (en) 2022-04-28
CL2012001696A1 (es) 2013-03-08
AU2010335950B2 (en) 2014-08-21
UY33154A (es) 2011-06-30
EP2516461A1 (en) 2012-10-31
WO2011075861A1 (en) 2011-06-30
US20180016350A1 (en) 2018-01-18
KR20170036137A (ko) 2017-03-31
TW201619383A (zh) 2016-06-01
JP2013515460A (ja) 2013-05-09
KR101758703B1 (ko) 2017-07-18
US8796425B2 (en) 2014-08-05
KR20170084357A (ko) 2017-07-19
TW201925228A (zh) 2019-07-01
RU2585534C2 (ru) 2016-05-27
ZA201202299B (en) 2014-06-25
US20210214461A1 (en) 2021-07-15
ZA201706443B (en) 2020-12-23
US10781268B2 (en) 2020-09-22
JP2021153603A (ja) 2021-10-07
JP5914353B2 (ja) 2016-05-11
US20150080555A1 (en) 2015-03-19
EP3498731A1 (en) 2019-06-19
CN109293768A (zh) 2019-02-01
ZA201402145B (en) 2018-05-30
JP2017121254A (ja) 2017-07-13
KR20120102061A (ko) 2012-09-17
EP4219545A1 (en) 2023-08-02
MX2012005345A (es) 2012-06-08
RU2012130945A (ru) 2014-01-27
CA2777527C (en) 2020-06-23
BR112012017051A2 (pt) 2017-12-05

Similar Documents

Publication Publication Date Title
MX352871B (es) Método para disminuir inmunogenicidad.
HUE053480T2 (hu) Eljárás domén ellenanyagok elõállítására
HUE051430T2 (hu) Eljárás variábilis domének elõállítására
MX2013001045A (es) Organoide hepatico, sus usos y metodo de cultivo para obtenerlos.
IL217381A0 (en) Optimizing the production of antibodies
GB2472482B (en) Contextual voice commands
IL200919A0 (en) Methods for generation of antibodies
HUE054566T2 (hu) Téglagyártási eljárás enzimtermelõ baktériumok felhasználásával
NZ621170A (en) Anti-human cd52 immunoglobulins
AU2013207589A1 (en) Anti-Siglec-15 Antibody
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
MY163339A (en) A method of producing ingenol-3-angelate
HUE069364T2 (hu) Eljárás immunglobulin variábilis egydomének elõállítására
PL2553082T3 (pl) Sposób i urządzenie do wytwarzania biogazu
IL205051A (en) Method for producing antibodies
GB2495884B (en) A method of increasing the effect of an activated-potentiated form of an antibody
EP2221384A4 (en) METHOD FOR MANUFACTURING ANTIBODY
MX2012010317A (es) ß-HIDROXIALQUILAMIDAS, METODO PARA SU PRODUCCION Y SU USO.
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
WO2010109185A3 (en) Process for the preparation of doxazosin and salts thereof
MX2012003888A (es) Semigeles de acido silicico de superficie modificada.
GB201020045D0 (en) Method for the treatment of biogas
MX2013002395A (es) Procedimiento de preparacion de ditiin-tetracarboximidas.
GB2480419B (en) Method for the manufacture of ethanol
HK1138884A (en) Methods for generation of antibodies